Exhibit
99.2
| Press
Release |
Media
Contact
Matthias
Link
T
+49 6172 609-2872
matthias.link@fmc-ag.com
Contact
for analysts and investors
Dr.
Dominik Heger
T
+49 6172 609-2601
dominik.heger@fmc-ag.com
www.freseniusmedicalcare.com |
May
3, 2022
Dr.
Carla Kriwet to succeed Rice Powell as Chief Executive Officer of Fresenius Medical Care
Dr.
Carla Kriwet (51) will become the new CEO of Fresenius Medical Care, the world's leading provider of products and services for individuals
with renal diseases, on January 1, 2023. The Supervisory Board of Fresenius Medical Care Management AG unanimously appointed her to succeed
Rice Powell (66), who in accordance with the company’s age limit for Management Board members is stepping down when his contract
ends on December 31, after 10 years heading the company. Like Rice Powell, Dr. Carla Kriwet will also be a member of the Management Board
of Fresenius Management SE. Helen Giza, Chief Financial Officer of Fresenius Medical Care, will enter a new five-year contract, and in
addition to her current positions as CFO and CTO will assume the position of Deputy CEO.
Dr.
Carla Kriwet was most recently CEO and President of BSH Hausgeräte GmbH, a company with €15.6 billion in sales, 62,000 employees
and 40 production plants around the world. From 2013 to 2020 she was with the health technology company Royal Philips N.V. in the United
States, since 2017 as a member of the company’s Executive Board. At Philips she headed the Connected Care division, which includes
the business areas Patient Care and Monitoring Solutions as well as Healthcare Informatics.
Previously,
Dr. Carla Kriwet was a member of the Executive Board of the non-governmental organization Save the Children Germany in Berlin, and Chief
Sales & Marketing Officer at the medical technology company Drägerwerk in Lübeck, Germany. Between 2003 and 2010 she held
various management positions in the strategy department and in the Healthcare division of Linde AG, lastly as Head of Linde Healthcare
Europe. Before that, she spent six years with the Boston Consulting Group, where, among other responsibilities, she headed consulting
projects in healthcare. Dr. Carla Kriwet started her career in project management at ABB Daimler-Benz Transportation in India in 1995,
after working as a volunteer for an SOS Children’s Village in Burundi and studying business at Switzerland’s University of
St. Gallen, where she graduated with a doctorate degree.
Rice Powell joined Fresenius Medical Care in 1997, and as CEO of Fresenius Medical
Care North America was appointed to the Management Board of Fresenius Medical Care in 2004. He has been the company’s CEO since
January 1, 2013. Under his direction, Fresenius Medical Care significantly extended its global leadership, identifying emerging business
areas such as value-based care and home dialysis early and then expanding successfully into them.
Rice
Powell said: “After 25 years with this company, and a full decade as CEO, I look back with a lot of gratitude and pride at what
we achieved during this time. Our products and services are more important than ever to our patients, and a fundamental part of their
lives. As the world’s only provider of the full range of innovative therapies and products for people with renal diseases, we have
outstanding prerequisites for our continued success. I want to thank all my colleagues – on the Management Board, the management
team, and everyone in all our facilities worldwide – for their untiring efforts and support over the years. I’m very happy
to know that our company will be in good hands in the future.”
Stephan
Sturm, Chairman of the Fresenius Medical Care Management AG Supervisory Board and CEO of Fresenius, said: “I am very thankful
to Rice Powell for his highly dedicated service over many years, and for his important contribution to our success. He played a key
role in shaping Fresenius Medical Care, initiated future-looking developments and set in motion the necessary transformation of the
company. On behalf of the entire Supervisory Board and the Management Board of Fresenius, I wish Rice all the very best for the next
stage of his life, with more time for his family and hobbies. At the same time, I am very much looking forward to working with Dr.
Carla Kriwet. I have come to know her as a highly skilled and bold manager with a lot of experience in the healthcare industry,
clear ideas and a lot of empathy. People’s health and well-being are very close to her heart, and something she has worked for
over the years in different organizations and constellations. I’m certain that working closely with Helen Giza, and together
with the entire management team, she will successfully shape the transformation now underway and manage the challenges, not least
those created by the pandemic, embrace with enthusiasm the numerous growth opportunities before us, and lead Fresenius Medical Care
to continued success.”
Dr.
Carla Kriwet said: “I am very much looking forward to taking on this new position and working together with my new colleagues.
I fully identify with the vision of making the lives of the patients who have put their trust in us a little more worth living every
day. And I’m convinced that bringing ever better medicine to ever more people goes hand in hand with economic success. Early in
my professional development, I found my way into the healthcare business and have remained very closely connected to it ever since. Fresenius
Medical Care is a globally active, leading and unique company that still has tremendous potential. I want to do my part to leverage this
potential for the benefit of patients and employees, and in doing so also add shareholder value.”
Fresenius
Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.8 million
patients worldwide regularly undergo dialysis treatment. Through its network of 4,171 dialysis clinics, Fresenius Medical Care provides
dialysis treatments for approximately 345,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis
products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the Company focuses on expanding
in complementary areas and in the field of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and
on the New York Stock Exchange (FMS).
For
more information visit the Company’s website at www.freseniusmedicalcare.com.
Disclaimer:
This
release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially
from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business,
economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical
studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing.
These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities
and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking
statements in this release.
